DGX

QUEST DIAGNOSTICS LABORATORY SERVICES ORDER ISSUED AGAINST BPA 15BNAS26A00000038 IAW FSS V797D-70090.

FY26 B1 QUEST LAB DIAGNOSTICS Q3 JUN QUEST DIAGNOSTICS-INMATE LABS FOR INMATE POPULATION. FOR ORDERING LIFE SUSTAINING NEEDS

FCI LEAVENWORTH QUEST DIAGNOSTICS LAB SERVICES GENERAL POPULATION IN JUNE 2026 IAW T&C: 15BNAS26A00000038 FSS NUMBER: V797D-70090

BPA: 15BNAS26A00000038 MAY 1, 2026 - MAY 31, 2026

FCI LEAVENWORTH QUEST DIAGNOSTICS LAB SERVICES US MARSHAL INMATES IN JUNE 2026 IAW T&C: 15BNAS26A00000038

FY26 B5 QUEST LAB TESTING APR 26 SCHEDULE NUMBER: V797D-70090

BPA: 15BNAS26A00000038 APRIL 1, 2026 - APRIL 30, 2026

FY26 B1 QUEST I/M LAB TESTING QTR 3 V797D-70090

FY26 B1 QUEST DIAGNOSTICS MAY

FY26 MAY B1 QUEST LABS 15BNAS26A00000038 V797D-70090 JAN-MARCH 2026

Federal policy related to strengthening the clinical laboratory workforce S. 2355 and H.R. 5582 - Patients Deserve Price Tags Act S.1816/H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 Appropriations related to clinical laboratory workforce, PFAS and cardiovascular disease testing S.2761 and H.R. 5269, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 H.R. 5571 - Expanding Seniors Access to PFAS Testing Act H.R. 6130 - Alzheimers Screening and Prevention Act of 2025 Federal policy related to coverage and reimbursement of clinical laboratory services under the Medicare program

Policies, rules, and regulations related to clinical laboratories and Medicare coverage policies. H.R.5269 - Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare payments for lab tests. S.2761 - RESULTS Act - Issues related to Medicare payments for lab tests. H.R. 7148 - Consolidated Appropriations Act, 2026 - issues related to clinical lab test reimbursement rates.

diagnostics, clinical lab reimbursement issues, savings access to lab service, supply chain physician fee schedule, savings access to lab services federal budget issues

Issues related to patient access and affordability of clinical laboratory testing. Issues related to the FY2026 budget and appropriations process Issues related to patient access and affordability of clinical laboratory testing. Issues related laboratory data collection and reimbursement under PAMA. H.R. 5269 - RESULTS Act S. 2761 - RESULTS Act

Appropriations related to clinical laboratory workforce, PFAS and cardiovascular disease testing Federal policy and programs regarding oncology research and development related to cancer screening, diagnosis, and survivorship Federal policy related to strengthening the clinical laboratory workforce Food and Drug Administration (FDA) policies related to diagnostics and laboratory regulation S. 2355 and H.R. 5582 - Patients Deserve Price Tags Act S.1816/H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 Diagnostics and chronic disease prevention and treatment S.2761 and H.R. 5269, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 H.R. 5571 - Expanding Seniors Access to PFAS Testing Act Federal policy related to coverage and reimbursement of clinical laboratory services under the Medicare program Regulatory changes to Sec. 216 of the Protecting Access to Medicare Act of 2014 (PAMA)

Federal policy and programs regarding oncology research and development related to cancer screening, diagnosis, and survivorship Federal policy related to strengthening the clinical laboratory workforce Food and Drug Administration (FDA) policies related to diagnostics and laboratory regulation Federal price transparency legislation related to clinical laboratories S.1816/H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 P.L. 118-22/H.R. 6363 - Further Continuing Appropriations and Other Extensions Act, 2024, provisions related to Medicare reimbursement for clinical diagnostics and pathology laboratory services Federal policy related to coverage and reimbursement of clinical laboratory services under the Medicare program Appropriations related to clinical laboratory workforce, PFAS and cardiovascular disease testing

Federal policy and programs regarding oncology research and development related to cancer screening, diagnosis, and survivorship Federal policy related to strengthening the clinical laboratory workforce Food and Drug Administration (FDA) policies related to diagnostics and laboratory regulation Federal price transparency legislation related to clinical laboratories S.1816/H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 H.R. 5571 - Expanding Seniors Access to PFAS Testing Act S.2761 and H.R. 5269, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 P.L. 118-22/H.R. 6363 - Further Continuing Appropriations and Other Extensions Act, 2024, provisions related to Medicare reimbursement for clinical diagnostics and pathology laboratory services Federal policy related to coverage and reimbursement of clinical laboratory services under the Medicare program Appropriations related to clinical laboratory workforce, PFAS and cardiovascular

Policies, rules, and regulations related to clinical laboratories and Medicare coverage policies. H.R.5269 - Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare payments for lab tests. S.2761 - RESULTS Act - Issues related to Medicare payments for lab tests.

diagnostics, clinical lab reimbursement issues, savings access to lab service, supply chain physician fee schedule, savings access to lab services federal budget issues

Issues related to patient access and affordability of clinical laboratory testing. Issues related laboratory data collection and reimbursement under PAMA. H.R. 5269 - RESULTS Act S. 2761 - RESULTS Act Issues related to patient access and affordability of clinical laboratory testing. Issues related to the FY2026 budget and appropriations process